Abnormal contingent negative variation in HIV patients receiving antiretroviral therapy

Neuroreport. 2003 Nov 14;14(16):2111-5. doi: 10.1097/00001756-200311140-00020.

Abstract

The contingent negative variation, an event-related potential related to neural activity in the frontal lobe and basal ganglia, neuropsychological tests and structural MRI were used to examine CNS function and structure in HIV-positive patients receiving antiretroviral therapy. Relative to controls, HIV patients had smaller thalamic volume and reduced late contingent negative variation amplitude that correlated with caudal atrophy. Behaviorally, viremic patients were more impaired than virally suppressed patients and controls on neuropsychological measures of psychomotor speed, selective attention and mental flexibility. These results suggest that antiretroviral therapy may not be effective in protecting cortical and subcortical structures against HIV-related neuropathology, regardless of immune function. However, the benefits of antiretroviral therapy on immune function appear to facilitate neurocognitive performance.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Anti-Retroviral Agents / pharmacology*
  • Atrophy / pathology
  • Atrophy / physiopathology
  • Brain / drug effects*
  • Brain / pathology
  • Brain / physiopathology*
  • Caudate Nucleus / pathology
  • Cognition Disorders / complications
  • Cognition Disorders / diagnosis
  • Cognition Disorders / physiopathology
  • Evoked Potentials / drug effects*
  • Evoked Potentials / physiology
  • HIV Infections / complications
  • HIV Infections / drug therapy
  • HIV Infections / physiopathology*
  • Humans
  • Magnetic Resonance Imaging
  • Middle Aged
  • Neuropsychological Tests
  • Psychomotor Disorders / complications
  • Psychomotor Disorders / diagnosis
  • Psychomotor Disorders / physiopathology
  • Reaction Time / drug effects
  • Thalamus / pathology
  • Viremia / drug therapy
  • Viremia / physiopathology

Substances

  • Anti-Retroviral Agents